Date: 2015-02-13
Type of information: Nomination
Compound:
Company: Sage Therapeutics (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 13, 2015, Sage Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, announced the appointment of Amy Schacterle, Ph.D., as vice president of regulatory affairs and quality assurance and Erin Lanciani as vice president of human resources. Dr. Schacterle brings to SAGE extensive expertise in regulatory affairs and quality assurance, with 22 years of experience in the biotech and life science industries, including 15 years in executive management. She most recently served as vice president, regulatory affairs at Sunovion Pharmaceuticals (previously Sepracor), where she worked for 10 years, also serving as executive director and senior director of regulatory affairs. At Sunovion, she led regulatory strategy regarding clinical development of CNS compounds and later managed development and commercial regulatory activities for all drug, biologic and combination device products at the company\'s Marlborough campus. Prior to Sunovion, Dr. Schacterle spent seven years leading the regulatory affairs function at Stryker Biotech, where she determined successful regulatory strategies for biologic orthopaedic products and was an integral part of the quality team. Dr. Schacterle received her B.S. in biomedical engineering at Rensselaer Polytechnic Institute and her Ph.D. and M.S. in biomedical engineering at the University of Virginia. Dr. Schacterle was recently named as one of Boston Business JournalMass High Tech 2014 Women to Watch. Erin Lanciani brings more than 20 years of experience in developing human resources strategies and programs to the company. Before joining SAGE, Ms. Lanciani served as executive director, human resources, global commercialization at Bristol-Myers Squibb, joining the company through its October 2007 acquisition of Adnexus, where she was the vice president of human resources and a member of the executive leadership team. In 2009, Erin relocated to Paris where she was the HR director for European markets at BMS and served as a strategic business partner responsible for all aspects of HR across multiple European commercial, R&D and corporate functions. Prior to BMS, Ms. Lanciani was vice president of human resources at Therion Biologics and also served as the director of human resources for ViaCell, as a human resources business partner at Genzyme Corporation and was a founder/partner of Outsourcing Solutions, Inc., a human resources consulting firm. She earned her B.S. in business administration from Northeastern University.
Financial terms:
Latest news:
